CSF2 and neoplasm: Since replication of T-VEC in the addressed tumor sites is accompanied by a continuous release of immunostimulatory GM-CSF (being encoded in T-VEC as a transgene (39)) notable changes in the composition of the respective tumor micro-environments are triggered.